You are here
Spring Bank Pharmaceuticals, Inc. to Present at the 2018 Cantor Global Healthcare Conference
HOPKINTON, Mass., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, chairman, president and chief executive officer of Spring Bank will present at the upcoming 2018 Cantor Global Healthcare Conference taking place on October 1-3 at the Intercontinental New York Barclay Hotel in New York, NY. Presentation details are as follows:
2018 Cantor Global Healthcare Conference
Date: October 3, 2018
Time: 11:30 am
Location: Empire Ballroom 2
About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to selectively target and modulate the activity of specific proteins implicated in various disease states. The company’s lead product candidate, inarigivir soproxil, is being developed for the treatment of chronic hepatitis B virus (HBV). Inarigivir is designed to selectively activate within infected cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense. The company is also developing its lead STING (Stimulator of Interferon Genes) agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers.
For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Chief Financial Officer
LifeSci Advisors, LLC
Andrew McDonald, Ph.D.